Krystal Biotech 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Krystal Biotech reported third-quarter 2026 global net revenue of $127.3 million, up 30% from $97.8 million in the third quarter of 2025, and net income of $63.1 million, or $2.05 per diluted share.
- The company ended September with more than $1.2 billion in cash and investments and said it had generated approximately $1.1 billion in revenue since launch.
- U.S. net revenue was $95.3 million; the company reported more than 760 reimbursement approvals, over 80 new prescribers added during the quarter, and approximately 80% of patients self-administering Visovec.
- Visovec international revenue was $32 million in the third quarter; more than 20 centers in Germany had initiated patients, France recorded its first home administration through the retrocession pathway, and Japan continued adding patients and prescribers.
- Gross margin was 94%, compared with 96% in the third quarter of 2025; cost of goods sold was $7.6 million, R&D expenses were $14.9 million, and G&A expenses were $33.7 million.
- Management reported encouraging initial KB113 results in three patients with Garland syndrome: over 80% of assessed lesions regressed, more than half regressed by over 50%, and biopsies confirmed complete clearance of one injected tumor in each patient.
- Enrollment in the KB111 repeat-dose study for Haley-Haley disease was complete with five patients; KB803 enrolled three additional patients, KB801 enrollment continued at 22 U.S. sites, and KB407 was dosing three patients in its repeat-dose study.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and thank you for standing by, and welcome to Krystal Biotech's third quarter 2026 earnings conference call. At this time, all participants are on a listen-only mode. After the speakers' presentations, there will be a question-and-answer session. During the question-and-answer session, there will be a limit of 2 questions per participant. As a reminder, today's conference is being recorded. I would now like to hand the conference over to your host, Stéphane Paquette, Senior Vice President of Corporate Development.
Please begin. Good morning, and thank you all for joining today's call.
Earlier today, we released our financial results for the third quarter of 2026. The press release is available on our website at www.krystalbio.com. We also filed our earnings 8-K and 10-Q with the SEC earlier today. Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer, Suma Krishnan, President of Research and Development, Laurent Goux, Executive Vice President and General Manager for Europe, Christine Wilson, Senior Vice President and Head of U.S. Commercial, and Kate Romano, Chief Accounting Officer. This conference call will, and our responses to questions may, contain forward-looking statements.
You are cautioned not to rely on these forward-looking statements, which are based on current expectations using the information available as of the date of this call, and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties, and other factors can be found in our SEC filings. With that, I'll turn the call over to Krish.
Good morning, and thank you for joining us. Q3 was another strong Q for Krystal. We delivered $127.3 million in VYJUVEK revenue, an increase of 30% from the same period last year, and reported diluted earnings of $2.05 a share, and ended September with $1.2 billion in cash and investments. Those results, they reflect a business that's growing, that's profitable, and generating the resources to advance our pipeline. They also reflect the work our teams have done to build Krystal into a global company with commercial operations, manufacturing capabilities, clinical development programs that we own and control. Today, we have generated approximately $1.1 billion in VYJUVEK revenues since launch, and that is an important milestone for a medicine developed here at Krystal.
Behind that number are so many patients receiving treatment, physicians incorporating a new paradigm of genetic medicines into their practices, and families gaining access to a medicine that addresses the underlying cause of DEB. in the U.S., demand continues to grow, as does the prescribing physician base. Internationally, we continue to translate physician interest into patient starts across Germany, France, and Japan. The pricing secured for VYJUVEK in Japan and Germany and Italy to date reflects recognition of the meaningful benefits that VYJUVEK provides patients and families. I am proud of our team's thoughtful work to demonstrate that value and establish a strong foundation for patient access internationally. We will continue to build on this progress in ensuing pricing discussions across additional markets, and Laurent will discuss those markets in more detail. We also made meaningful progress in development.
We were really encouraged by the recent Gorlin syndrome data clinical results that demonstrated regression in both injected and non-injected lesions, together with the histologically confirmed clearance of an injected lesion in each patient. That gives us a very strong foundation to have conversations with the FDA on next steps. I want to address the updated timing of some of our clinical readouts. While we had hoped to share these readouts sooner, I want to be clear that the programs continue to progress well, and we look forward to sharing results in the upcoming months. Suma will elaborate more in a few minutes. Alongside these developments, our board authorized a share repurchase program of up to $400 million that we expect to deploy over the next two years.
We have reached a position where our financial resources allow us to support global commercial expansion, pipeline and clinical development, and have the flexibility to return capital to shareholders. The authorization reflects our confidence in Krystal's long-term prospects and our responsibility to allocate this capital thoughtfully. Taken altogether, this Q demonstrated the strength of the business we built. It demonstrated continued commercial growth, substantial profitability, and progress across the pipeline. For that, I would like to thank our employees, our investigators, and the patients and families participating in our studies for helping make that progress possible. With that, I will turn it over to our team to walk through commercial, clinical, and financial updates.
Thank you, Krish. VYJUVEK international revenue reached $32 million in the third quarter. We continue to translate physician interest into patient starts while strengthening the growth foundations through reimbursement progress and greater access to treatment at home. In Germany, pricing negotiations have concluded, providing greater visibility as we expand our reach across the country. More than 20 centers have now initiated patients on VYJUVEK, up circa 15% from last quarter. Doing so, we continue to broaden the treatment network to reach patients who are not routinely seen at established expert centers. In France, we achieved an important milestone with the first home administration through the retrocession pathway. This creates an opportunity to reduce the practical burden of treatment on patients and families, and support treatment continuity. We are now working to extend this approach to additional eligible patients and centers while national pricing discussions continue.
In Japan, our team is making steady progress, bringing new patients to treatment and expanding our prescriber network. We are also advancing support initiatives to help the EB community maximize the potential benefits of VYJUVEK therapy and navigate the complexity of VYJUVEK's GMO status. Looking ahead, pricing and reimbursement negotiation in Italy have also concluded, and we now expect to launch VYJUVEK in early 2027. In Spain, pricing discussions are progressing with a decision expected before the end of the year. Some patients already have access through exceptional regional funding arrangements, providing a foundation for a potential launch next year. We are also advancing regulatory and market access activities in additional countries to expand VYJUVEK's reach over time. Taking together, these developments give us confidence in the international opportunity. Health systems are recognizing VYJUVEK's value, physicians are gaining treatment experience, and barriers to administration are beginning to come down.
Our focus is on turning that progress into more patients starting and continuing treatment. With that, I'll hand the call over to Christine.
Thank you, Laurent. U.S. net revenue for the third quarter was $95.3 million, reflecting continued demand for VYJUVEK and our efforts to reach more patients. We have now secured more than 760 reimbursement approvals nationwide. During the quarter, we added over 80 new prescribers. This expanding physician base supports continued adoption, and we believe substantial opportunity remains among diagnosed patients who have not yet started treatment, as well as those who remain undiagnosed or misdiagnosed. We are also seeing the benefits of greater treatment flexibility. Approximately 80% of patients now self-administer VYJUVEK, helping patients and caregivers incorporate treatment into their wound care routines at home. As patients gain experience, our focus extends beyond treatment initiation to supporting continued use as their wound care needs evolve. Our VYJUVEK Voices and Krystal Connect programs provide education, practical support, and opportunities for patients and caregivers to learn from one another.
Engagement with physicians, advocacy organizations, and the broader DEB community also helps us understand barriers to treatment and improve the support we provide. Looking ahead, our priorities remain clear: reach more patients, expand the prescribing network, and support long-term treatment. With continued demand, a growing physician base, and greater flexibility in administration, we believe VYJUVEK is well-positioned for sustained U.S. growth. We are proud of the progress we have made and excited about the opportunities ahead as we continue working to establish VYJUVEK as the long-term standard of care for patients living with DEB. With that, I'll turn the call over to Suma.
Thank you, Christine, and good morning, everyone. We have encouraging progress to share this morning, including our initial Gorlin syndrome results, the upcoming Hailey-Hailey readout, and the ongoing dosing in cystic fibrosis. Before I get into the update, I want to acknowledge that some clinical results are going to take a bit longer than we initially expected. We recognize the importance of these milestones. Our teams are working diligently to advance each study, and we look forward to sharing the data as they become available. Importantly, the studies themselves are progressing well, and we remain encouraged by their eventual outcome. I'll walk through our rationale and expectations from here shortly. With that, I would like to start today's update with the latest addition to our pipeline, KB113 for Gorlin syndrome. Gorlin syndrome is a rare genetic disease estimated to affect more than 10,000 Americans.
Patients can develop hundreds of basal cell carcinomas, or BCCs, over their lifetime, requiring repeated surgeries that can lead to tissue loss, disfigurement, and significant psychological burden. With no therapy specifically approved for Gorlin syndrome, there is a substantial need for a safe, effective treatment to reduce BCC burden. KB707 is our HSV-1-based immunotherapy designed to drive sustained localized expression of human IL-2 and IL-12 in the tumor microenvironment and promote systemic immune-mediated tumor clearance. We recently completed a pilot study evaluating a low dose of intratumoral KB707, which we now refer to as KB113, in three adult patients with Gorlin syndrome. Each received six doses over 14 weeks. Investigators assessed regression in both injected and non-injected landmark BCCs throughout treatment and 30 days after the final dose using a pre-specified five-point scale.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
18 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
